Surgalign Holdings, Inc.

Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. Its products portfolio include cervical fixation, The Streamline (TL) fixation, motion preservation, orthobiologics, cervical inter-body fusion, TL IBF, and SI joint fusion. It offers coflex interlaminar stabilization device, SImmetry sacroiliac joint fusion system, and Fortilink IBF system with TETRAfuse?3D technology. The company was founded on February 12, 1998 and is headquartered in Deerfield, IL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RTI Surgical - OEM Business designs, develops, manufactures and distributes biologic, metal and synthetic implants for a global customer base. Its implants are used in a variety of surgical procedures including orthopaedic, spine, sports medicine, general surgery and trauma.

Surgalign Holdings (NASDAQ: SRGA ) stock is on the rise Tuesday after the company recently received a delisting notice alongside its bankruptcy filing. That delisting notice will result in the company's shares being removed from the Nasdaq Exchange at the start of business on July 3.

Why Is Surgalign Holdings (SRGA) Stock Up 10% Today?

Surgalign Holdings (NASDAQ: SRGA ) stock is taking a beating on Monday after the company revealed a delisting notice from the Nasdaq Exchange. This delisting notice has to do with the company's recent Chapter 11 bankruptcy filing.

Why Is Surgalign Holdings (SRGA) Stock Down 23% Today?

Delisting to take effect on July 3, 2023; Company's common stock is expected to begin trading on the OTC under the symbol SRGAQ Delisting to take effect on July 3, 2023; Company's common stock is expected to begin trading on the OTC under the symbol SRGAQ

Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing

Surgalign (NASDAQ: SRGA ) stock is taking a beating on Tuesday after the spine solutions company filed for Chapter 11 bankruptcy. As a result of this filing and plans to cut costs, several changes are coming to Surgalign.

Why Is Surgalign (SRGA) Stock Down 55% Today?

DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) (“Surgalign” or the “Company”) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. (“Xtant”) for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain of its subsidiaries, who elected to ﬁle voluntary petitions under chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division.

Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code

Surgalign (SRGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Surgalign (SRGA) Upgraded to Buy: What Does It Mean for the Stock?

Company to showcase its upgraded HOLO Portal™ Surgical Guidance System  and key products in its hardware spine and biologics portfolio

Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources

Surgalign Holdings, Inc. (NASDAQ:SRGA ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants David Lyle - Chief Financial Officer Terry Rich - President and Chief Executive Officer Chris Thunander - Chief Accounting Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to Surgalign Holdings 2023 First Quarter Results Conference Call and Webcast.

Surgalign Holdings, Inc. (SRGA) Q1 2023 Earnings Call Transcript

Surgalign Holdings (SRGA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to loss of $2.10 per share a year ago.

Surgalign Holdings (SRGA) Reports Q1 Loss, Tops Revenue Estimates

DEERFIELD, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2023 first quarter ended March 31, 2023.

Surgalign Announces First Quarter 2023 Results and Provides Update on its Business Operations

DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023.

Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023

Surgalign (SRGA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Surgalign Holdings (SRGA) Q1 Earnings Expected to Decline

DEERFIELD, Ill., April 13, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on April 10, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the $10 million minimum stockholders' equity requirement for continued listing on the NASDAQ Global Select Market under Nasdaq Listing Rule 5450(b)(1)(A). The notification letter further indicated that the Company does not meet alternative standards set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Select Market.

Surgalign Announces Receipt of Nasdaq Deficiency Notice and Intends to Submit Plan to Regain Compliance

Surgalign Holdings, Inc. (NASDAQ:SRGA ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants David Lyle - Chief Financial Officer Terry Rich - President and Chief Executive Officer Conference Call Participants Matt Hewitt - Craig-Hallum Operator Greetings, and welcome to the Surgalign Holdings 2022 Fourth Quarter and Year-End Conference Call. At this time, all participants are in a listen-only mode.

Surgalign Holdings, Inc. (SRGA) Q4 2022 Earnings Call Transcript

DEERFIELD, Ill., March 30, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for its fourth quarter and full year 2022 ending December 31, 2022.

Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2022 Results

DEERFIELD, Ill., March 21, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its fourth quarter and full year 2022 after the close of trading on March 30, 2023.

Surgalign Schedules Fourth Quarter and Full Year 2022 Earnings Release for March 30, 2023

DEERFIELD, Ill., March 16, 2023 (GLOBE NEWSWIRE) --  Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that it will be hosting its 2023 Annual Meeting of Shareholders virtually, on Thursday, June 1, 2023 at 9 a.m. PT.

Surgalign to Host its 2023 Annual Meeting of Shareholders on June 1, 2023

Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report 2022 revenue of approximately $82.0 million and end the year with a cash balance in excess of $16 million Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report 2022 revenue of approximately $82.0 million and end the year with a cash balance in excess of $16 million

Surgalign Provides Update on Corporate Restructuring Initiatives and Confirms its Prior 2022 Revenue Guidance

Dr. Rick C. Sasso, renowned spinal surgeon to highlight Surgalign's HOLO Portal™ Surgical Guidance System on the OrthoDome Panel on March 8, 2023 Dr. Rick C. Sasso, renowned spinal surgeon to highlight Surgalign's HOLO Portal™ Surgical Guidance System on the OrthoDome Panel on March 8, 2023

Surgalign to Participate at the 2023 AAOS Annual Meeting OrthoDome in Las Vegas

Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device

Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million

DEERFIELD, Ill., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced a key milestone for its recently introduced posterior fixation platform – the Cortera™ Spinal Fixation System.

Surgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

DEERFIELD, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced that the closing of its previously announced registered direct offering priced at the market under Nasdaq rules of 6,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and Series A warrants to purchase up to 6,000,000 shares of common stock and Series B warrants to purchase up to 1,500,000 shares of common stock at a combined offering price of $2.00 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants. The Series A warrants and the Series B warrants have an exercise price of $1.815 per share and will expire five years following the issuance date for the Series A warrants and three years following the issuance date for the Series B warrants.

Surgalign Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Company plans to realign in an effort to improve efficiencies, while lowering its capital requirements to invest in innovation; estimated cash savings in 2023 are expected to be approximately $30 - $35 million Company plans to realign in an effort to improve efficiencies, while lowering its capital requirements to invest in innovation; estimated cash savings in 2023 are expected to be approximately $30 - $35 million

Surgalign™ Announces Corporate Restructuring Program to Focus on Key Growth Areas

Surgalign Holdings, Inc. (NASDAQ:SRGA ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Terry Rich - Chief Executive Officer David Lyle - Chief Financial Officer Chris Thunander - Chief Accounting Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator Greetings, and welcome to the Surgalign Holdings 2022 Third Quarter Earnings Call. It is now my pleasure to introduce your host, David Lyle.

Surgalign Holdings, Inc. (SRGA) Q3 2022 Earnings Call Transcript

DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022.

News for Surgalign Holdings, Inc. Stock (SRGA)